MARKET

AMLX

AMLX

Amylyx Pharmaceuticals
NASDAQ
3.780
+0.130
+3.56%
Closed 18:23 03/24 EDT
OPEN
3.720
PREV CLOSE
3.650
HIGH
3.785
LOW
3.610
VOLUME
402.48K
TURNOVER
0
52 WEEK HIGH
7.27
52 WEEK LOW
1.575
MARKET CAP
334.92M
P/E (TTM)
-0.8536
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AMLX last week (0317-0321)?
Weekly Report · 1d ago
Weekly Report: what happened at AMLX last week (0310-0314)?
Weekly Report · 03/17 09:23
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga · 03/12 12:36
Weekly Report: what happened at AMLX last week (0303-0307)?
Weekly Report · 03/10 09:23
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy
NASDAQ · 03/07 15:58
Cautious Hold Rating for Amylyx Pharmaceuticals Amid Key Clinical Updates and Stable Financial Position
TipRanks · 03/07 08:02
Amylyx Pharmaceuticals Co-CEOs Cash In on Stock Sales!
TipRanks · 03/06 02:02
Amylyx Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Dow Jones · 03/05 13:19
More
About AMLX
More
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.
Recently
Symbol
Price
%Change

Webull offers Amylyx Pharmaceuticals Inc stock information, including NASDAQ: AMLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMLX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMLX stock methods without spending real money on the virtual paper trading platform.